Published in Support Care Cancer on January 28, 2005
Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the Functional Assessment of Cancer Therapy-Neutropenia (FACT-N). Support Care Cancer (2007) 0.88
A cost-effectiveness analysis of adjuvant chemoradiotherapy for resected gastric cancer. Gastrointest Cancer Res (2008) 0.82
The hospital anxiety and depression scale. Acta Psychiatr Scand (1983) 121.58
The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res (2002) 22.73
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med (1966) 7.30
Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol (2003) 5.16
Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics (1999) 4.86
Mucositis: Its Occurrence, Consequences, and Treatment in the Oncology Setting. Oncologist (1998) 1.52
Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood (1992) 1.45
Factor analysis of the Hospital Anxiety and Depression Scale from a large cancer population. Psychol Psychother (2002) 1.40
Quality of life after adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat (2000) 1.33
The Cancer Care Monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. J Pain Symptom Manage (2003) 1.16
Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J Pain Symptom Manage (2000) 1.05
Current considerations in the management of fever and neutropenia. Curr Clin Top Infect Dis (1999) 0.84
Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life. J Clin Oncol (1996) 0.82
Controversies in the treatment of neutropenia in cancer patients. Curr Opin Hematol (1998) 0.80
Colony-stimulating factors: clinical applications. Pharmacotherapy (1992) 0.77
Adverse events associated with chemotherapy for common cancers. Pharmacotherapy (2000) 0.75
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res (2006) 4.28
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care (2013) 3.90
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol (2008) 3.66
Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 2.56
Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J Clin Oncol (2009) 2.48
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol (2013) 2.27
Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol (2010) 2.12
Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw (2014) 1.71
Small N designs for rehabilitation research. J Rehabil Res Dev (2012) 1.42
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract (2011) 1.38
Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer (2007) 1.20
The Cancer Care Monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. J Pain Symptom Manage (2003) 1.16
Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother (2006) 1.15
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer (2012) 1.14
The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with cancer. J Clin Sleep Med (2009) 1.09
Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2013) 1.06
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res Treat (2014) 1.05
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer (2008) 1.04
Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. J Pain Symptom Manage (2006) 1.04
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2017) 0.99
Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study. Support Care Cancer (2008) 0.98
A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep (2003) 0.97
A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol (2008) 0.95
Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer (2003) 0.95
Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine. Heart Rhythm (2008) 0.92
Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol (2009) 0.91
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. Am J Manag Care (2011) 0.91
Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group. Br J Haematol (2013) 0.91
Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer. Cancer Chemother Pharmacol (2003) 0.89
Lessons learned from the institution of the Surgical Care Improvement Project at a teaching medical center. Am J Surg (2009) 0.88
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. Cancer (2013) 0.87
Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities. BMC Cancer (2004) 0.86
Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting. Oncologist (2013) 0.85
The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting. Pancreas (2013) 0.83
A prospective investigation of chemotherapy-induced neutropenia and quality of life. J Support Oncol (2006) 0.82
Symptom Burden for Patients with Metastatic Colorectal Cancer Treated with First-Line FOLFOX or FOLFIRI with and Without Bevacizumab in the Community Setting. Support Cancer Ther (2007) 0.82
Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer. Breast (2009) 0.81
Experiencing neutropenia: quality of life interviews with adult cancer patients. BMC Nurs (2005) 0.80
Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin. Clin Cancer Res (2002) 0.80
Indirect costs associated with metastatic breast cancer. J Med Econ (2013) 0.80
A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer (2009) 0.80
Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases. J Med Econ (2012) 0.80
Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Clin Breast Cancer (2005) 0.79
Symptom Burden and Quality of Life in Patients with Follicular Lymphoma undergoing Maintenance Treatment with Rituximab Compared with Observation. Ther Adv Hematol (2011) 0.78
Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. J Clin Oncol (2006) 0.78
G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. Cancer Med (2014) 0.78
Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden. Clin Lung Cancer (2009) 0.78
The Zero Acceptance of Pain (ZAP) Quality Improvement Project: evaluation of pain severity, pain interference, global quality of life, and pain-related costs. J Pain Symptom Manage (2003) 0.78
Early treatment discontinuation and switching in first-line metastatic breast cancer: the role of patient-reported symptom burden. Breast Cancer Res Treat (2014) 0.77
Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer. Support Care Cancer (2009) 0.77
The AIM Higher Initiative: new procedures implemented for assessment, information, and management of chemotherapy toxicities in community oncology clinics. Clin J Oncol Nurs (2008) 0.76
Are we winning the war on cancer? J Oncol Pract (2011) 0.75
Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review. Adv Ther (2014) 0.75
The Patient Care Monitor-Neutropenia Index: development, reliability, and validity of a measure for chemotherapy-induced neutropenia. Oncol Nurs Forum (2011) 0.75
Greater physical and psychological symptom burden in patients with grade 3/4 chemotherapy-induced neutropenia. Support Cancer Ther (2006) 0.75
Are we winning the war on cancer? Am J Manag Care (2011) 0.75
If at first you don't succeed, don't quit, try again: The Centers For Medicare and Medicaid Services demonstration project on quality of care--2005 and 2006. J Support Oncol (2006) 0.75
Sex differences in patients who have cancer with mild anemia: symptom burden and quality of life. Support Cancer Ther (2005) 0.75
Large-aperture fast multilevel Fresnel zone lenses in glass and ultrathin polymer films for visible and near-infrared imaging applications. Appl Opt (2014) 0.75
Supra-Therapeutic Oral Paracetamol Overdose in Adults: An Update for the Dental Team. Dent Update (2017) 0.75
Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer. Cancer (2011) 0.75
Are we winning the war on cancer? Am J Manag Care (2012) 0.75